Overview

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy

Status:
Not yet recruiting

Trial end date:
2025-12-03

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo, Inc.

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Carboplatin
Paclitaxel